| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
16α-Hydroxytrametenolic acid targets the retinoid X receptor (RXR), functioning as a potential selective agonist. RXRs are nuclear receptors that play important roles in various biological processes including cell differentiation, metabolism, and development. They function as obligate heterodimer partners for many other nuclear receptors, including retinoic acid receptors (RARs), thyroid hormone receptors, and vitamin D receptors. By modulating RXR activity, 16α-Hydroxytrametenolic acid may influence these diverse signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, 16α-Hydroxytrametenolic acid has been characterized as a potential retinoid X receptor (RXR) selective agonist. The compound's activity is typically assessed in cell-based reporter assays using RXR response element (RXRE)-luciferase constructs. As a naturally occurring triterpene, its activity may be compared to that of synthetic RXR agonists. The compound's selectivity for RXR over other nuclear receptors would be confirmed through parallel assays. Further studies are needed to fully characterize its potency and efficacy.
|
| ln Vivo |
Specific in vivo activity data for 16α-Hydroxytrametenolic acid are not extensively documented in the publicly available literature. As a potential RXR agonist, the compound may have applications in studying RXR-mediated biological processes including metabolism, cell differentiation, and development. Further in vivo studies are needed to characterize its bioavailability, efficacy, and safety. The compound is a naturally occurring triterpene, which may have implications for its pharmacokinetic properties.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 16α-Hydroxytrametenolic acid typically involve competitive binding experiments using RXR proteins and radiolabeled or fluorescently labeled RXR ligands as tracers. The compound's binding affinity to RXR is assessed, with IC₅₀ or Kd values determined. Assays are conducted in buffered solutions at physiological pH with appropriate receptor preparations. The compound's agonist activity is confirmed through functional assays measuring RXR-mediated transcriptional activation using RXRE-luciferase reporter constructs.
|
| Cell Assay |
In vitro cell-based assays for 16α-Hydroxytrametenolic acid utilize cell lines expressing RXR to assess its agonist activity. Cells are treated with varying concentrations of the compound for 24-48 hours. RXR-mediated transcriptional activity is evaluated using reporter gene assays with RXRE-luciferase constructs. The expression of RXR target genes can be measured by qPCR. Selectivity for RXR over other nuclear receptors is assessed using parallel assays. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed.
|
| Animal Protocol |
In vivo animal studies with 16α-Hydroxytrametenolic acid would typically involve administration of the compound to rodent models to evaluate its effects on RXR-mediated processes. Potential study designs include models of metabolic diseases, where RXR plays a role in lipid and glucose metabolism. Typical endpoints would include measurements of metabolic parameters, assessment of RXR target gene expression in target tissues, and pharmacokinetic profiling. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
16α-Hydroxytrametenolic acid has a molecular weight of 472.70 g/mol and a molecular formula of C₃₀H₄₈O₄. Its IUPAC name is (R)-2-((3S,5R,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-methylhept-5-enoic acid. It is a naturally occurring triterpene. As a natural product, its pharmacokinetic properties may be influenced by its physicochemical characteristics. Further studies are needed to characterize its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
16α-Hydroxytrametenolic acid is intended for research use only and is not approved for human therapeutic applications. As a research chemical derived from natural sources, comprehensive toxicological data are not available in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. As with all research chemicals, comprehensive toxicological profiling would be required before any consideration for clinical development.
|
| References | |
| Additional Infomation |
16α-Hydroxytrametenolic acid (CAS#: 176390-68-4) has a molecular formula of C₃₀H₄₈O₄ and a molecular weight of 472.70 g/mol. Its IUPAC name is (R)-2-((3S,5R,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-methylhept-5-enoic acid. It is a naturally occurring triterpene and a potential retinoid X receptor (RXR) selective agonist. This compound is not a drug and has not undergone clinical trials for therapeutic use.
|
| Molecular Formula |
C30H48O4
|
|---|---|
| Exact Mass |
472.355
|
| CAS # |
176390-68-4
|
| PubChem CID |
132285301
|
| Appearance |
White to off-white solid powder
|
| Density |
1.11±0.1 g/cm3(Predicted)
|
| Boiling Point |
598.3±50.0 °C(Predicted)
|
| LogP |
6.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
896
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(=CCC[C@H]([C@H]1[C@@H](C[C@@]2([C@@]1(CCC3=C2CCC4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C)O)C(=O)O)C
|
| InChi Key |
LPHOGVFYEBRXSC-LUXVNGTFSA-N
|
| InChi Code |
InChI=1S/C30H48O4/c1-18(2)9-8-10-19(26(33)34)25-22(31)17-30(7)21-11-12-23-27(3,4)24(32)14-15-28(23,5)20(21)13-16-29(25,30)6/h9,19,22-25,31-32H,8,10-17H2,1-7H3,(H,33,34)/t19-,22-,23?,24+,25+,28-,29-,30+/m1/s1
|
| Chemical Name |
(2R)-2-[(3S,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
